TheEdgeResearch
Home / Stocks / NDTP

NDT Pharmaceuticals Inc. (NDTP)

OTC Healthcare Biotechnology
$0.15 ▲ +42.31%
Market Cap
$29.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.00
52-Wk Range
0.015-2.1
CEO
James Hovis
Country
US
Currency
USD

NDT Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vienna, VA, US. The stock last traded at $0.15, up 42.31% on the session, giving a market capitalisation of $29.2M. On trailing twelve-month figures it carries a trailing P/E of -0.76, a net margin of -4372.3%. Its beta of 0.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.76
Price / Sales
33.18
Price / Book
18.39
EV / EBITDA
-33.24
Gross margin
-155.7%
Operating margin
-271.0%
Net margin
-4372.3%
Return on equity
—
Debt / equity
0.44
Current ratio
3.83
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
0
IPO date
2008-01-22
Headquarters
Vienna, VA, US
About NDT Pharmaceuticals Inc.

NDT Pharmaceuticals Inc., a biotechnology firm situated in Vienna, Virginia, is dedicated to formulating a range of treatments for serious neurological ailments, particularly those stemming from traumatic brain injuries.

Comparable companies

NDT Pharmaceuticals Inc. is most often compared with the following Healthcare names:

ALECATHEBMNDFNERVNEUPNGNENMRANRSNNTHIQNTM
More research on NDTP
NDTP technical analysis NDTP TheEdge Score Compare against peers
Open full interactive analysis & DCF →